{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:25Z","timestamp":1789140685841,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the 2-year real-world outcomes of switching to intravitreal faricimab in patients with neovascular age-related macular degeneration (nAMD) previously treated with anti-VEGF agents and unable to extend treatment intervals (TI) beyond 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective cohort study including patients with nAMD managed under a treat-and-extend regimen who required frequent anti-VEGF injections (&lt;\u200912-week intervals) to maintain retinal dryness. Patients were switched to faricimab without a loading phase and followed for a minimum of 2 years. TI were extended in 4-week increments based on anatomical response. The primary outcome was change in TIl; secondary outcomes included change in best-corrected visual acuity (BCVA) and identification of predictors of response. \u201cOptimal responders\u201d were defined as eyes achieving\u2009\u2265\u20098-week interval extension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 110 eyes from 97 patients were included (mean age 78.7\u2009\u00b1\u20099.8 years). Prior to switching, the mean TI was 6.18\u2009\u00b1\u20092.05 weeks, which increased significantly to 13.61\u2009\u00b1\u20095.62 weeks at the last follow-up visit (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). BCVA remained stable over 2 years (0.42\u2009\u00b1\u20090.24 vs. 0.43\u2009\u00b1\u20090.25;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0117). At final follow-up, 68.2% of eyes achieved intervals\u2009\u2265\u200912 weeks, 20.0% \u226516 weeks, and 24.6% reached\u2009\u2265\u200920-week intervals. Overall, 89.1% of eyes experienced interval extension. Optimal responders accounted for 47.3% of eyes and were significantly younger and had received fewer prior injections (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab in previous treated nAMD patients enabled meaningful extension of TI over 2 years while maintaining stable visual acuity. These findings support faricimab as an effective strategy to reduce treatment burden in patients who are difficult to extend with prior anti-VEGF therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00916-0","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:55:37Z","timestamp":1785858937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Two-year real-world effectiveness of faricimab after treatment switch in neovascular age-related macular degeneration"],"prefix":"10.1186","volume":"12","author":[{"given":"Jorge","family":"Ruiz-Medrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4497-5542","authenticated-orcid":false,"given":"Margarita","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota Moreno","family":"de Alboran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Ruiz-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"916_CR1","doi-asserted-by":"publisher","first-page":"1077e1084","DOI":"10.1136\/bjophthalmol-2019-314422","volume":"104","author":"JQ Li","year":"2020","unstructured":"Li JQ, Welchowski T, Schmid M, et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020;104:1077e1084.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"916_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology"},{"key":"916_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060.","journal-title":"Ophthalmology"},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","volume":"160","author":"JL Prenner","year":"2015","unstructured":"Prenner JL, Halperin LS, Rycroft C, et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160:725\u2013e7311. https:\/\/doi.org\/10.1016\/j.ajo.2015.06.023.","journal-title":"Am J Ophthalmol"},{"issue":"10326","key":"916_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729\u201340.","journal-title":"Lancet"},{"issue":"8","key":"916_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE Investigators. TENAYA and LUCERNE: Two-Year results from the phase 3 neovascular Age-Related macular degeneration trials of faricimab with Treat-and-Extend dosing in year 2. Ophthalmology. 2024;131(8):914\u201326.","journal-title":"Ophthalmology"},{"key":"916_CR7","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/OPTH.S231801","volume":"15","author":"AM Khanani","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, et al. Angiopoietins as Potential Targets in Management of Retinal Disease. Clin Ophthalmol. 2021;15:3747\u201355. https:\/\/doi.org\/10.2147\/OPTH.S231801. Published 2021 Sep 4.","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"916_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2020;34(5):802\u20134. https:\/\/doi.org\/10.1038\/s41433-019-0670-1.","journal-title":"Eye (Lond)"},{"issue":"1","key":"916_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-025-00776-0","volume":"12","author":"J Ruiz-Medrano","year":"2025","unstructured":"Ruiz-Medrano J, Pana I, Garc\u00eda-Zamora M, Flores-Moreno I, Puertas M, Ruiz-Moreno JM. Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. Int J Retina Vitreous. 2025;12(1):5. https:\/\/doi.org\/10.1186\/s40942-025-00776-0 . PMID: 41350718; PMCID: PMC12781570.","journal-title":"Int J Retina Vitreous"},{"key":"916_CR10","doi-asserted-by":"publisher","unstructured":"Ambati NR, Leone A, Brill D, Sisk RA. Real-World long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration. Retina. 2024;11. https:\/\/doi.org\/10.1097\/IAE.0000000000004322.","DOI":"10.1097\/IAE.0000000000004322"},{"issue":"16","key":"916_CR11","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (Lond). 2024;38(16):3059\u201364.","journal-title":"Eye (Lond)"},{"issue":"1","key":"916_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","volume":"262","author":"K Kataoka","year":"2024","unstructured":"Kataoka K, Itagaki K, Hashiya N, Wakugawa S, Tanaka K, Nakayama M, for Japan AMD Research Consortium (JARC). Six-month outcomes of switching from Aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(1):43\u201351.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"916_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","volume":"9","author":"G Grimaldi","year":"2025","unstructured":"Grimaldi G, Ambresin A, Pfister IB, Schild C, Plasencia C, Hatz K, et al. One-Year outcomes after switching to faricimab in eyes with pretreated neovascular Age-Related macular degeneration: A Swiss retina research network report. Ophthalmol Retina. 2025;9(9):838\u201347.","journal-title":"Ophthalmol Retina"},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.2147\/OPTH.S483563","volume":"18","author":"Y Qaseem","year":"2024","unstructured":"Qaseem Y, Hou KK, Pettenkofer MS. Outcomes after switching to faricimab for refractive macular edema in Treatment-Experienced eyes with neovascular Age-Related macular degeneration. Clin Ophthalmol. 2024;18:3097\u2013102.","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"916_CR15","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-Year Real-World outcomes of intravitreal faricimab for previously treated neovascular Age-Related macular degeneration. Ophthalmol Ther. 2024;13(11):2985\u201397.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"916_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, et al. Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab. Ophthalmol Retina. 2025;9(1):22\u201330. https:\/\/doi.org\/10.1016\/j.oret.2024.07.020.","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"916_CR17","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00417-024-06377-1","volume":"262","author":"H Koizumi","year":"2024","unstructured":"Koizumi H, Gomi F, Tsujikawa A, Honda S, Mori R, Ochi H, Iwasaki K, Okada AA, TENAYA. Investigators. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefes Arch Clin Exp Ophthalmol. 2024;262(8):2439\u201348. https:\/\/doi.org\/10.1007\/s00417-024-06377-1 . Epub 2024 Mar 14. PMID: 38483611; PMCID: PMC11271316.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"916_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.oret.2026.02.001","volume":"10","author":"A Ambresin","year":"2026","unstructured":"Ambresin A, Chaudhary V, Gale R, et al. Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration. Ophthalmol Retina. 2026;10(5):573\u20135. https:\/\/doi.org\/10.1016\/j.oret.2026.02.001.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00916-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:33:28Z","timestamp":1788276808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00916-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00916-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent to participate in the study has been obtained from all participants. The study was approved by the Ethics Committee of Puerta de Hierro University Hospital under protocol number 31\/25.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}